Access restricted to higher education institution's students and staff
master's thesis
Liječenje raka dojke kod žena u postmenopauzi

Sara Tibauth (2015)
Metadata
TitleLiječenje raka dojke kod žena u postmenopauzi
AuthorSara Tibauth
Mentor(s)Renata Dobrila-Dintinjana (thesis advisor)
Abstract
Rak dojke je najčešće dijagnosticirani maligni tumor u žena u svijetu, sa više od milijun slučajeva svake godine. Čini skoro 25% tumora u žena , uzrokuje oko 15% smrti zbog karcinoma te se zato danas smatra jednim od najvećih javnozdravstvenih problema. Različiti su čimbenici rizika koji su uključeni u proces nastanka raka dojke: spol, dob, pozitivna obiteljska anamneza, nerotkinje, rana menarha i kasna menopauza,zračenje,debljina,oralni kontraceptivi/hormonska nadomjestna terapija, dijagnoza dobroćudnih parenhimatoznih bolesti dojke te životne navike. Terapijski ciljevi su određeni stupnjem proširenja same bolesti. Kod lokalnog, primarno operabilnog raka dojke inicijalni terapijski postupak je kirurški zahvat, bilo mastektomija ili jedan od poštednih vrsta zahvata. Nakon primarnog zbrinjavanja tumora ordinira se adjuvantna terapija (radioterapija, hormonska ili kemoterapija) u cilju uništenja mogućih zaostalih dijelova tumora. Kod ordiniranja hormonske adjuvantne terapije potrebno je odrediti da li je bolesnica u menopauzi ili još nije. Kao „zlatni standard“ hormonske terapije u premenopauzalnih žena koristi se tamoksifen, dok „zlatni standard“ u liječenju postmenopauzalnih žena jesu aromatazni inhibitori. U slučaju lokalnog i primarno neoperabilnog tumora dojke primjenjuje se neoadjuvantna vrsta terapije, kojom smanjujemo veličinu primarnog tumora i osiguravamo odgovarajući kirurški zahvat. Svrha liječenja metastatskog raka dojke je maksimalno dugo preživljenje, a uz to i briga o kvaliteti života bolesnice. U liječenju metastatske bolesti primjenjuju se svi terapijski modaliteti: kemoterapija, radioterapija, hormonska terapija, tirozin-kinazni inhibitori, angiostatička terapija te potporna simptomatska terapija. Petogodišnje preživljenje za sve stadije raka dojke u razvijenim zemljama svijeta iznosi oko 85-90%.
Keywordsbreast cancer risk factors menopause treatment
GranterSveučilište u Rijeci
Medicinski fakultet
Lower level organizational unitsKatedra za onkologiju i radioterapiju
PlaceRijeka
StateCroatia
Scientific field, discipline, subdisciplineBIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Gynecology and Obstetrics
Study programme typeuniversity
Study levelintegrated undergraduate and graduate
Study programmeMedicine
Academic title abbreviationdr. med.
Genremaster's thesis
Language Croatian
Defense date2015
Parallel abstract (English)
Breast cancer is most frequently diagnosed malignancy, accounting for over a million cases each year. This disease makes almost 25% of tumors in women, causing about 15% deaths due to cancer and is therefore considered as one of the greatest public health problems today. There are many different risk factors involved in the process of developing breast cancer: gender, aging, family history of breast cancer, early menarche and late menopause, diagnosis of benign breast disease, radiation, obesity, oral contraceptives/hormon replacement therapy and lifestyle. Therapeutic goals are determinated with the expansion of disease. With the local, primary operable breast cancer initial therapeutic procedure is surgery, either mastectomy or one of the non-radical type of surgery. After primary care of the tumor, adjuvant therapy (radiotherapy, hormonal or chemotherapy) is administered to destroy possible remaining part of the tumor. For administration of hormonal adjuvant therapy is necessary to determine whether the patients in menopause or not. "Gold standard" of hormonal therapy in premenopausal women is tamoxifen, while the "gold standard" in the treatment of postmenopausal women are aromatase inhibitors. In case of local or unresectable breast tumors, we apply neoadjuvant type of therapy, which reduces the size of the primary tumor and provide appropriate surgical procedure. The purpose of the treatment of metastatic breast cancer is maximum prolonged time survival, in addition to the concern about the quality of life of the patient. In the treatment of metastatic disease we apply all therapeutic modalities: chemotherapy, radiotherapy, hormonal therapy, tyrosine-kinase inhibitors, angiostatic therapy and supportive treatment. The five-year survival rate for all stages of breast cancer in developed countries is about 85-90%
Parallel keywords (Croatian)rak dojke rizični čimbenici menopauza terapija
Resource typetext
Access conditionAccess restricted to higher education institution's students and staff
Terms of usehttp://rightsstatements.org/vocab/InC/1.0/
URN:NBNhttps://urn.nsk.hr/urn:nbn:hr:184:008516
CommitterBosa Licul